Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
215 result(s)
GSKpro for UK healthcare professionals
A portal for UK healthcare professionals containing GSK product information, patient resources, exclusive webinars and more
Ordering and delivery
Find out how to set up an account and start ordering GSK vaccines.
Ellipta critical error studies in COPD
Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their COPD patients
XEVUDY ▼ (sotrovimab)
XEVUDY▼ (sotrovimab) label information for patients and healthcare professionals in Great Britain, including summary of product characteristics and patient information leaflet.
DECTOVA▼
zanamivir IV</br> Influenza
Report a possible side effect | GSKpro
Information for UK healthcare professionals on how to report an adverse event related to a GSK product
This summer, how can GSK help you deliver the non-seasonal shingles National Immunisation Programme?
AREXVY▼
Respiratory Syncytial Virus Vaccine, Adjuvanted<br>Vaccines
Respiratory
Overview of COPD and severe asthma.
Burden of disease landing page
Page explaining burden of disease. | This website contains promotional information about NUCALA (mepolizumab) and is for UK healthcare professionals only.
BLENREP▼
belantamab mafodotin
COPD Guidelines
Information about COPD Guidelines and CV Risk to support UK healthcare professionals
Contact | GSKpro UK
GSK UK contact page for healthcare professionals.
Request a contact
Contact us form for UK healthcare professionals to contact GSK
GSKpro Home | SHINGRIX
SHINGRIX information for UK healthcare professionals only
Coming soon | GSKpro
This page is under construction. If you require assistance, please connect with our Customer Support team via live chat or request to be contacted by a suitable GSK contact.
Webinars & events | GSKpro
A collection of promotional events and webinars featuring experts for UK healthcare professionals
GSKpro Implementation | SHINGRIX (Herpes Zoster vaccine recombinant, adjuvanted)
SHINGRIX information for UK healthcare professionals only
Webinars & events | GSKpro
A collection of promotional events and webinars featuring experts for UK healthcare professionals
GSK Trelegy – Homepage
Trelegy Ellipta Homepage. GSKPro for UK healthcare professionals.
Relvar Ellipta (fluticasone furoate/vilanterol)
Relvar Ellipta (fluticasone furoate/vilanterol pre-dispensed inhalation powder) information for Healthcare Professionals registered in Ireland.
JEMPERLI ▼
dostarlimab<br>Oncology
Therapy areas | GSKpro UK
Learn about GSK’s product portfolio in respiratory, vaccines, oncology and more. This page is for UK healthcare professionals only.
Second Dose
Understanding the importance of the second dose of SHINGRIX (herpes zoster vaccine recombinant, adjuvanted) | This website contains promotional information about SHINGRIX and is for UK healthcare professionals only
GSKpro Patient Referrals | SHINGRIX
Shingles National Immunisation Programme information for UK healthcare professionals only
GSK Trelegy - Comparative Effectiveness Study
Trelegy Ellipta Comparative Effectiveness Study. GSKPro for UK healthcare professionals.
Resources | GSKpro
For UK HCPs. Support your patients and practice with these healthcare resources, ranging from training devices to patient support information.
OMJJARA▼
momelotinib<br>Oncology
GSKpro SHINGRIX overview | SHINGRIX
SHINGRIX information for UK healthcare professionals only
Immunocompromised | SHINGRIX
SHINGRIX information for UK healthcare professionals only
Immunocompromised Clinical Data | SHINGRIX
SHINGRIX information for UK healthcare professionals only
Discontinued products | GSK Pro
Discontinued products
GSKpro Safety | SHINGRIX
SHINGRIX information for UK healthcare professionals only
BLENREP▼ (belantamab mafodotin) MoA | GSK UK
BLENREP▼ (belantamab mafodotin) is a BCMA-targeted therapy for multiple myeloma that combines targeted mAbs with cytotoxic drugs. For UK HCPs only.
BLENREP ▼ (belantamab mafodotin): Multiple myeloma second-line treatment outcomes | GSK UK
Explore the challenges of treating relapsed and refractory multiple myeloma, and the unmet need for effective second-line treatment options. For UK HCPs only.
DREAMM-8 BLENREP▼ (belantamab mafodotin) Trial | GSK UK
Overview of DREAMM-8 phase 3 trial investigating BLENREP▼triplet therapy (BPd) vs a pomalidomide triplet (PVd) for multiple myeloma. For UK HCPs only.
BLENREP▼ (belantamab mafodotin) : managing side effects
Managing eye-related and non-eye-related side effects of BLENREP (belantamab mafodotin). For UK HCPs only.
BLENREP▼ (belantamab mafodotin) Dosing and administration | GSK UK
Explore BLENREP▼ (belantamab mafodotin) dosing and administration, including info on schedules, reductions, delays and infusion time. For UK HCPs only
Supporting patients on BLENREP▼ (belantamab mafodotin)
Guidance for UK healthcare professionals to support patients on BLENREP (belantamab mafodotin). For UK HCPs only.
BLENREP ▼ (belantamab mafodotin) + Pd: Clinical trial efficacy & safety data | GSK UK
Review the BLENREP (belantamab mafodotin) + Pd efficacy and safety data from the Phase III DREAMM-8 trial. For UK HCPs only.
DREAMM-7 BLENREP▼ (belantamab mafodotin) Trial | GSK UK
Overview of DREAMM-7 phase 3 trial investigating triplet therapy (BLENREP▼ +Vd) vs a daratumumab triplet (DVd) for multiple myeloma. For UK HCPs only.
BLENREP▼ (belantamab mafodotin) resources
Access resource materials to support BLENREP (belantamab mafodotin) implementation in practice and to help your patients receiving BLENREP. For UK HCPs only.
Zejula (niraparib) | Get in touch
Zejula (niraparib)|Get in touch | This page contains the contacts for local GSK Oncology Representatives for Zejula (niraparib)|For UK Healthcare professionals only
ZEJULA
niraparib<br>Oncology
Products | GSKpro
GSK product information for UK healthcare professionals
Zejula (niraparib) | Mechanism of Action in Ovarian Cancer
Zejula (niraparib) | MoA | This page contains promotional information about the mechanism of action for Zejula in ovarian cancer. |For UK Healthcare professionals only
Zejula (niraparib) | Expert Perspectives
Zejula (niraparib)| Expert Perspectives | This page contains promotional information about Expert Perspectives on Zejula (niraparib), real patient case studies and best practices|For UK Healthcare professionals only
Zejula (niraparib) | About Zejula (niraparib)
Zejula (niraparib) UK | About Zejula | This page contains promotional information about Zejula (niraparib), and links to the funding, mechanism of action, resources, and contact page|For UK Healthcare professionals only
The multiple myeloma experts | GSK UK
Learn more about the BLENREP▼ (belantamab mafodotin) experts at GSK. For UK HCPs only.
GSKpro Impact of Shingles | SHINGRIX
SHINGRIX information for UK healthcare professionals only
Vaccines
GSK UK information about our vaccines
BLENREP▼ (belantamab mafodotin) + Vd: Clinical trial efficacy & safety data | GSK UK
Review the BLENREP (belantamab mafodotin) + Vd efficacy and safety data from the Phase III DREAMM-7 trial. For UK HCPs only.
IMT Guidelines
Information about COPD Guidelines to support UK healthcare professionals
ICS/LABA
Information about ICS/LABA in COPD to support UK healthcare professionals
BLENREP▼ (belantamab mafodotin) | GSK UK
BLENREP (belantamab mafodotin) in two different treatment combinations is approved for use in patients with multiple myeloma at first relapse. For UK HCPs only.
Nucala (mepolizumab) Home UK
Nucala (mepolizumab) UK | Home | This page contains promotional information about Nucala (mepolizumab). For UK Healthcare Professionals only.
Nucala (mepolizumab) Safety
Nucala (mepolizumab) UK | Safety | This page contains safety and promotional information about Nucala (mepolizumab). For UK Healthcare Professionals only.
Efficacy | Nucala (mepolizumab)
Key Nucala (mepolizumab) efficacy data | This website contains promotional information and is for UK healthcare professionals only.
BLENREP▼ (belantamab mafodotin) news and updates | GSK UK
Stay informed with the latest news and updates on BLENREP (belantamab mafodotin). For UK HCPs only.
Supply
Information to be provided to Healthcare Professionals on GSK’s medicines and vaccines supply availability
COPD Treatment Support | Trelegy Ellipta Resources on GSKPro
Access guideline aligned COPD information, evidence summaries and practical clinical resources designed for healthcare professionals. Sign in to GSKPro for full access
GSKpro Common Comorbidities | SHINGRIX
Shingles National Immunisation Programme information for UK healthcare professionals only
No results. Why not try:
- Checking the spelling of the search term
- Trying a different search term
- Resetting or revising the filter settings (if you used filters to do this search)
Show more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
